Melanie J. Percy, Mayka Sanchez, Sabina Swierczek, Mary Frances McMullin, Mariluz P. Mojica-Henshaw, Martina U. Muckenthaler, Josef T. Prchal and Matthias W. Hentze

Is congenital secondary erythrocytosis/polycythemia caused by activating mutations within the HIF-2α iron-responsive element?
References


To the editor:

Is congenital secondary erythrocytosis/polycythemia caused by activating mutations within the HIF-2α iron-responsive element?

Study of inherited polycythemia/erythrocytosis has revealed defects in the oxygen-sensing pathway and provided insights into the regulation of erythropoietin (Epo) synthesis by hypoxia inducible factor (HIF). HIF is a dimer consisting of α and β subunits. Two different α isoforms exist: HIF-1α, which is ubiquitously expressed, and HIF-2α or EPAS1, which is limited to specific tissues. The constitutively expressed HIF-β subunit is not hypoxia regulated. In normoxia, the HIF-1α and HIF-2α proteins are rapidly degraded through a complex interaction with one of several iron-containing prolyl hydroxylases (PHDs), leading to the binding of the von Hippel Lindau protein (pVHL), ubiquitination, and degradation by the proteasome. This interaction constitutes the
“hypoxia sensing” since hypoxia and iron deprivation leads to a posttranslational increase in both HIF-1α and HIF-2α proteins and increased transcription of an array of their target genes.2

The recent discovery of an iron-responsive element (IRE) in the 5′ untranslated region (UTR) of HIF2A reveals a novel regulatory link between iron availability and HIF2A expression.3 In iron deficiency, the iron regulatory proteins (IRPs) repress the translation of HIF-2α protein by binding to its 5′ IRE.3 Recent data implicates HIF-2α in the control of renal, hepatic, and brain Epo production in vivo.3,7 Altogether, these data indicate new molecular connections between HIF2A expression, erythropoiesis, and iron availability.

Polycythemia/erythrocytosis can be associated with raised Epo levels, which are indicative of a deregulated oxygen-sensing pathway. Indeed, defects in VHL and PHD2 have been described in a minority of patients.8-10 We hypothesized that germ-line mutations in the 5′ IRE of the HIF2A gene would uncouple HIF-2α synthesis from negative translational control, predicting polycythemia/erythrocytosis with increased Epo levels (Figure 1). Consequently, a group of 147 such individuals referred to Belfast or Salt Lake City was screened for defects in the 5′ IRE by PCR-direct sequencing (Figure 1). The sequence in all 294 alleles was in full concordance with the published genomic sequence of HIF2A (EPAS1, RefSeq: AC016696, nucleotide 81298–81330).11 However, 4 single-nucleotide polymorphisms (SNPs) were detected (Figure 1B). According to the Entrez SNP database,12 the T allele for the rs17039192 SNP (nucleotide 81261; Figure 1) is present in the Japanese population at a frequency of 0.14. Within the group of 120 patients referred to Belfast, 3 T alleles were detected in individuals from China and Vietnam. Of the 27 patients with polycythemia studied in Salt Lake City, this T allele was not detected. However, we found 3 previously unreported SNPs at 3′ of the IRE at nucleotides 81405, 81411, and 81424; their allele frequencies in 27 patients with polycythemia were 0.85, 0.69, and 0.37, respectively; these did not meaningfully differ from 25 control participants, whose frequencies were 0.58, 0.20, and 0.28. We conclude that the loss of iron-regulated control of HIF-2α translation by the IRP/IRE regulatory system is not the cause of polycythemia/erythrocytosis in a large collection of patients collected from the United Kingdom, Europe, and North and Central America.

Melanie J. Percy, Mayka Sanchez, Sabina Swierczek, Mary Frances McMullin, Mariluz P. Mojica-Henschaw, Martina U. Muckenthaler, Josef T. Prchal, and Matthias W. Hentze

The first three authors contributed equally to this study.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Melanie J. Percy, Department of Haematology; Floor C, Tower Block, Belfast City Hospital, Lisburn Road, Belfast, BT9 7AB, Northern Ireland; e-mail: melanie.percy@belfasttrust.hscni.net.

References

To the editor:

Antithrombin Cambridge II (A384S): prevalence in patients of the Paris Thrombosis Study (PATHROS)

The antithrombin (AT) Cambridge II (A384S), which results from a nucleotide (nt) G to T substitution at position 13268 of the gene (numbering system from Olds et al1), is a variant associated with borderline or mildly reduced antithrombin heparin cofactor activity, but normal immunologic level. This AT variant was initially reported in 4 unrelated heterozygotes, 3 of them being asymptomat-ic.2 Later, it was found in a cohort of 9669 blood donors in West Scotland in 10 nonrelated individuals (prevalence, 1.14 per 1000); despite former exposure of most of these donors to at-risk situations, only 1 of them had a history of venous thrombosis (VT),3 suggesting that the mutation may be a mild risk factor for VT; haplotype analysis performed in 18 families (including 12 families of blood donors) suggested that the mutation had at most 4 independent origins in the United Kingdom.

Recently, Corral et al studied the prevalence of the AT A384Smutation in Spain.4 In this large case-control study of venous thromboembolism (1018 patients/1018 healthy volunteers), the AT Cambridge II was found in 0.2% of volunteers and 1.7% of patients (odds ratio [OR] 9.75; 95% confidence interval [95% CI], 2.2-42.5). The results suggested that the Cambridge II variant may be a prevalent genetic risk factor for VT and the most frequent cause of AT deficiency in European populations.

We have investigated the prevalence of this mutation in patients from the case-control Paris Thrombosis Study (PATHROS). Recruitment criteria and the characteristics of this study were previously reported.5 The study was approved by local ethics committee, and all participants gave their informed consent. Briefly, consecutive patients with at least 1 established episode of deep VT or pulmonary embolism were recruited from a university hospital in Paris. A total of 88% of patients were born in Europe. Thrombophilia screening included AT activity measurement (Stachrom ATT; Diagnostica Stago, Asnières, France).

Genotyping for the AT A384S mutation was performed on genomic DNA by amplification-digestion; the exon 6 of the AT

From www.bloodjournal.org at USTAV HEMATOLOGIE A KREVNI on January 13, 2009. For personal use only.